


***What Is Claimed Is:***

1. A compound having the Formula I:



Formula I

5 or a pharmaceutically acceptable salt or a prodrug thereof, wherein:

R<sub>1</sub> is alkyl, haloalkyl, aminoalkyl, C<sub>1-10</sub> alkylaminoalkyl, di(C<sub>1-10</sub>)alkylaminoalkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, cyanoalkyl, alkanoylamidoalkyl, alkanoyloxyalkyl, azidoalkyl, alkenyloxyalkyl, or alkoxyalkyl;

10 R<sub>6</sub> and R<sub>7</sub> are taken together to form a five or six membered carbocyclic or heterocyclic ring;

15 R<sub>5</sub> and R<sub>8</sub> are independently selected from the group consisting of hydrogen, halogen, haloalkyl, aryl, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, hydroxyalkyl, nitro, amino, cyano, alkanoylamido, hydroxy, thiol, alkanoyloxy, alkoxy, carboxy, carbonylamido and thioalkoxy;

X is O or S; and

Y is optionally substituted aryl or optionally substituted heteroaryl;

20 with the proviso that

when R<sub>6</sub> and R<sub>7</sub> are taken together as -OCH<sub>2</sub>O-, then Y is not 2-thienyl, unsubstituted phenyl or a phenyl group that is substituted with a non-fused substituent;

when  $R_6$  and  $R_7$  are taken together as  $-\text{OCH}_2\text{O}-$  and Y is 3,4-methylenedioxyphenyl,  $R_1$  is not  $\text{C}_{1-3}$  alkyl,  $\text{C}_{3-6}$  cycloalkyl, or  $\text{C}_{3-6}$  cycloalkyl- $\text{C}_{1-3}$  alkyl; or


when  $R_6$  and  $R_7$  are taken together as  $-\text{OCH}_2\text{CH}_2\text{O}-$ , then Y is not unsubstituted phenyl or a phenyl group that is substituted with a non-fused substituent.

2. A compound according to claim 1, wherein X is O, and Y is a substituted or unsubstituted heteroaryl group.

3. A compound according to claim 1, wherein  $R_6$  and  $R_7$  taken together are  $-\text{OCH}_2\text{O}-$ ,  $-\text{OCH}_2\text{CH}_2\text{O}-$ ,  $-\text{O}-\text{CF}_2-\text{O}-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{OCH}_2\text{CH}_2-$ , or  $-\text{N}(\text{R}_9)-\text{CO}-\text{O}-$ ; wherein  $\text{R}_9$  is optionally substituted lower alkyl.

4. A compound according to claim 1, said compound is 1-isopropyl-6,7-methylenedioxy-4-(3-quinolinyl)quinazolin-2(1H)-one.

5. A compound according to claim 1, wherein



$\text{R}_2$  is H, alkyl, halo, amino, alkoxy, and nitro; and

$\text{R}_3$  and  $\text{R}_4$  are taken together to form a five or six membered carbocyclic or heterocyclic ring,

with a proviso that when both  $R_6$  and  $R_7$  and  $R_3$  and  $R_4$  are taken together as  $-OCH_2O-$ , then  $R_1$  is not  $C_{1-5}$  alkyl,  $C_{3-6}$  cycloalkyl, or  $C_{3-6}$  cycloalkyl- $C_{1-3}$  alkyl.

5            6.     A compound according to claim 5, wherein  $R_3$  and  $R_4$  taken together are  $-OCH_2O-$ ,  $-OCH_2CH_2O-$ ,  $-O-CF_2-O-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2-$ ,  $O-CH_2-CH_2-$ ,  $-N=CH-O-$ ,  $-NH-CO-O-$ ,  $-CH=CH-CH=CH-$ , or  $-O-CH=CH-$ .

10           7.     A compound according to claim 1, wherein said compound is selected from the group consisting of:

- 1-ethyl-6,7-methylenedioxy-4-(2-naphthyl)quinazolin-2(1H)-one,  
1-isopropyl-6,7-methylenedioxy-4-(2-naphthyl)quinazolin-2(1H)-one,  
1-cyclopropylmethyl-6,7-methylenedioxy-4-(3,4-methylenedioxy-  
15 phenyl)quinazolin-2(1H)-one,  
1-(2-diethylaminoethyl)-6,7-methylenedioxy-4-(3,4-methylenedioxy-phenyl)quinazolin-2(1H)-one,  
1-(2-propynyl)-6,7-methylenedioxy-4-(3,4-methylenedioxy-phenyl)quinazolin-2(1H)-one,  
20 1-isopropyl-6,7-(difluoromethylenedioxy)-4-(3,4-methylenedioxy-phenyl)quinazolin-2(1H)-one,  
1-isopropyl-6,7-methylenedioxy-4-(2,3-dihydro-5-benzopuranyl)-quinazolin-2(1H)-one,  
1-isopropyl-6,7-methylenedioxy-4-(6-chloro-3,4-methylenedioxy-phenyl)quinazolin-2(1H)-one,  
25 1-isopropyl-6,7-methylenedioxy-4-(5-indanyl)quinazolin-2(1H)-one,  
1-(2-morpholinoethyl)-6,7-methylenedioxy-4-(3,4-methylenedioxy-phenyl)quinazolin-2(1H)-one,  
1-isopropyl-6,7-methylenedioxy-4-(3,4-difluoromethylenedioxy-phenyl)quinazolin-2(1H)-one,  
30

1-(1-methyl-2-dimethylaminoethyl)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazolin-2(1*H*)-one,

1-isopropyl-6,7-methylenedioxy-4-(3-quinolinyl)quinazolin-2(1*H*)-one,

5 1-(2-aminoethyl)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-quinazolin-2(1*H*)-one,

1-isopropyl-6,7-methylenedioxy-4-(5-benzoxazolyl)quinazolin-2(1*H*)-one, and


10 1-(2-pyrrolidinoethyl)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazolin-2(1*H*)-one.

8. A compound according to claim 5, wherein said compound is selected from the group consisting of:

15 1-(2-dimethylaminoethyl)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazolin-2(1*H*)-one, and

1-(2-dimethylaminoethyl)-6,7-methylenedioxy-4-(3,4-ethylenedioxyphenyl)quinazolin-2(1*H*)-one.

20 9. A compound having the Formula II:



Formula II

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

25 R<sub>1</sub> is alkyl, haloalkyl, aminoalkyl, C<sub>1-10</sub> alkylaminoalkyl, di(C<sub>1-10</sub>)alkylaminoalkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl,

heteroaralkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, cyanoalkyl, alkanoylamidoalkyl, alkanoyloxyalkyl, azidoalkyl, alkenyloxyalkyl, or alkoxyalkyl;

$R_6$  and  $R_7$  are taken together to form a five or six membered carbocyclic or heterocyclic ring;

$R_5$  and  $R_8$  are independently selected from the group consisting of hydrogen, halogen, haloalkyl, aryl, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, hydroxyalkyl, nitro, amino, cyano, alkanoylamido, hydroxy, thiol, alkanoyloxy, alkoxy, carboxy, carbonylamido and thioalkoxy;


$n$  is 0 or 1;

$Y$  is optionally substituted aryl or optionally substituted heteroaryl; and  $z$  is 0 or 1;

with the proviso that when  $R_6$  and  $R_7$  are taken together as  $-OCH_2O-$ ,  $R_1$  is alkyl and  $z$  is 0, then  $Y$  is not 3-indazolyl.

10. The compound according to claim 9, wherein  $R_6$  and  $R_7$  taken together are  $-OCH_2O-$ ,  $-OCH_2CH_2O-$ ,  $-O-CF_2-O-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2-$ ,  $-OCH_2CH_2-$  or  $-N(R_9)-CO-O-$ ; wherein  $R_9$  is optionally substituted lower alkyl.

11. A compound according to claim 9, wherein,  $n$  is 1;  $z$  is 0 or 1;



$R_2$  is H, alkyl, halo, amino, alkoxy, or nitro; and

$R_3$  and  $R_4$  are taken together to form a five or six membered carbocyclic or heterocyclic ring.

12. The compound according to claim 11, wherein  $R_3$  and  $R_4$  taken together are  $-OCH_2O-$ ,  $-OCH_2CH_2O-$ ,  $-O-CF_2-O-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2-$ ,  $-O-CH_2-CH_2-$ ,  $-N=CH-O-$ ,  $-NH-CO-O-$ ,  $-CH=CH-CH=CH-$ , or  $-O-CH=CH-$ .

13. A compound according to claim 9, wherein said compound is selected from the group consisting of:

2-(2-diethylaminoethoxy)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline,


2-(2-dimethylaminoethoxy)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline,

2-(2-dimethylaminoethoxy)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline,

2-(2-aminoethoxy)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline, and

2-(2-pyrrolidinoethoxy)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline.

14. A compound according to claim 9, wherein  $n$  is 0;  $z$  is 0;



$R_2$  is H, alkyl, halo, amino, alkoxy, or nitro; and

R<sub>3</sub> and R<sub>4</sub> are taken together to form -OCH<sub>2</sub>O-, -OCH<sub>2</sub>CH<sub>2</sub>O-,  
-O-CF<sub>2</sub>-O-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -N=CH-O-,  
-NH-CO-O-, -CH=CH-CH=CH-, or -O-CH=CH-.

5            15.    A compound according to claim 14, wherein said compound is  
selected from the group consisting of:

2-methyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-  
quinazoline,

10            2-(1-hydroxy-1-methyl)ethyl-6,7-methylenedioxy-4-(3,4-methylene-  
dioxyphenyl)quinazoline,

6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline,

2-ethyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-  
quinazoline,

15            2-benzyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-  
quinazoline,

2-dimethylamino-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-  
quinazoline,

2-(2-diethylaminoethyl)-6,7-methylenedioxy-4-(3,4-methylene-  
dioxyphenyl)quinazoline,

20            2-(2-chloroethyl)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-  
quinazoline,

2-(2-dimethylaminomethyl)-6,7-methylenedioxy-4-(3,4-methylene-  
dioxyphenyl)quinazoline,

25            2-chloromethyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-  
quinazoline,

2-(2-dimethylamino-1-methylethoxy)-6,7-methylenedioxy-4-(3,4-  
methylenedioxyphenyl)quinazoline,

2-(3-chloropropyl)-6,7-methylenedioxy-4-(3,4-  
methylenedioxyphenyl)quinazoline,

2-(3-aminopropyl)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline,

2-*n*-pentyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-quinazoline,

5           2-(imidazol-1-yl)methyl-6,7-methylenedioxy-4-(3,4-methylene-dioxyphenyl)quinazoline,

6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-2-(1,2,4-triazol-1-yl)methyl-quinazoline,

10           2-((1-methyl-2-imidazolyl)thio)methyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline,

2-(imidazol-1-yl)ethyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline,

2-iodomethyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline,

15           2-acetoxymethyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline,

2-(2-morpholinoethyl)-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline, and


20           2-piperazinomethyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline.

25

30



16. A compound according to claim 9, wherein n is 0; z is 1;



R<sub>2</sub> is H, alkyl, halo, amino, alkoxy, or nitro; and

R<sub>3</sub> and R<sub>4</sub> are taken together to form -OCH<sub>2</sub>O-, -OCH<sub>2</sub>CH<sub>2</sub>O-, -O-CF<sub>2</sub>-O-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -N=CH-O-, -NH-CO-O-, -CH=CH-CH=CH-, or -O-CH=CH-.

17. A compound according to claim 16, wherein said compound is selected from the group consisting of:

6,7-Methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline 3-oxide,

2-Chloromethyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-quinazoline 3-oxide,

2-Ethyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline 3-oxide,

2-Methyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)-quinazoline 3-oxide,


2-(1-Imidazolyl)methyl-6,7-methylenedioxy-4-(3,4-methylenedioxyphenyl)quinazoline 3-oxide,

6,7-Methylenedioxy-4-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-methyl-quinazoline 3-oxide,

2-Dimethylaminomethyl-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxyquinazoline-3-oxide, and

2-Methylaminomethyl-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxyquinazoline 3-oxide.

18. A compound having the Formula III:



Formula III

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R<sub>1</sub> is alkyl, haloalkyl, aminoalkyl, C<sub>1-10</sub> alkylaminoalkyl, di(C<sub>1-10</sub>)alkylaminoalkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, cyanoalkyl, alkanoylamidoalkyl, alkanoyloxyalkyl, azidoalkyl, alkenyloxyalkyl, or alkoxyalkyl;

R<sub>6</sub> and R<sub>7</sub> are taken together to form a five or six membered carbocyclic or heterocyclic ring;

R<sub>5</sub> and R<sub>8</sub> are independently selected from the group consisting of hydrogen, halogen, haloalkyl, aryl, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, hydroxyalkyl, nitro, amino, cyano, alkanoylamido, hydroxy, thiol, alkanoyloxy, alkoxy, carboxy, carbonylamido and thioalkoxy;


X is O or S; and

Y is optionally substituted aryl or optionally substituted heteroaryl.

19. The compound of claim 18, wherein R<sub>6</sub> and R<sub>7</sub> taken together are -OCH<sub>2</sub>O-, -OCH<sub>2</sub>CH<sub>2</sub>O-, -O-CF<sub>2</sub>-O-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-,

-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -OCH<sub>2</sub>CH<sub>2</sub>-, or -N(R<sub>9</sub>)-CO-O-; wherein R<sub>9</sub> is optionally substituted lower alkyl.

20. A compound according to claim 18, wherein:



R<sub>2</sub> is H, alkyl, halo, amino, alkoxy, or nitro; and

R<sub>3</sub> and R<sub>4</sub> are taken together to form a five or six membered carbocyclic or heterocyclic ring.

21. The compound according to claim 20, wherein R<sub>3</sub> and R<sub>4</sub> taken together are -OCH<sub>2</sub>O-, -OCH<sub>2</sub>CH<sub>2</sub>O-, -O-CF<sub>2</sub>-O-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -N=CH-O-, -NH-CO-O-, -CH=CH-CH=CH-, or -O-CH=CH-.

22. A compound according to claim 18, wherein said compound is selected from the group consisting of:

2-[2-(Dimethylamino)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2-Ethyl-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2-[2-(1-Imidazolyl)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

4-(3,4-Methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2-[2-(1-Piperidiny)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,


2[2-(1-Pyrrolidiny)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone, and

5 2-[2-(Ethoxycarbonyl)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone.

23. A pharmaceutical composition comprising the compound of any one of claims 1, 9 and 18 and a pharmaceutically acceptable carrier.

10 24. A method of treating, preventing or ameliorating neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia or surgery; or treating or ameliorating a neurodegenerative disease selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's  
15 disease, Parkinson's disease and Down's syndrome; or treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids; or treating, preventing or ameliorating anxiety, psychosis, convulsions, acute or chronic pain, migraine headache, glaucoma, retinitis, urinary incontinence or inducing anesthesia; or enhancing learning and  
20 cognition; or treating or ameliorating schizophrenia and myoclonus; comprising administering to an animal in need of such treatment an effective amount of a compound of any one of claims 1, 9 and 18.

25. The method of claim 24, wherein:



$R_2$  is H, alkyl, halo, amino, alkoxy, or nitro; and

$R_3$  and  $R_4$  are taken together to form  $-OCH_2O-$ ,  $-OCH_2CH_2O-$ ,  $-O-CF_2-O-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2-$ ,  $-O-CH_2-CH_2-$ ,  $-N=CH-O-$ ,  $-NH-CO-O-$ ,  $-CH=CH-CH=CH-$ , or  $-O-CH=CH-$ .

26. The method according to claim 24, wherein said method is for treating, preventing or ameliorating global ischemia.


27. The method of claim 26, wherein said global ischemia is the result of cardiac arrest.

28. The method according to claim 24, wherein said method is for treating or ameliorating amyotrophic lateral sclerosis.

29. The method according to claim 24, wherein said method is for treating or ameliorating acute or chronic pain.

30. A method of treating, preventing or ameliorating schizophrenia, comprising administering to an animal in need thereof an effective amount of a compound of any one of claims 1, 9 and 18.


31. The method of claim 30, wherein:



R<sub>2</sub> is H, alkyl, halo, amino, alkoxy, or nitro; and

R<sub>3</sub> and R<sub>4</sub> are taken together to OCH<sub>2</sub>O-, -OCH<sub>2</sub>CH<sub>2</sub>O-, -O-CF<sub>2</sub>-O-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -N=CH-O-, -NH-CO-O-, -CH=CH-CH=CH-, or -O-CH=CH-.

32. A method of treating, preventing or ameliorating neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia or surgery; or treating or ameliorating a neurodegenerative disease selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome; or treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids; or treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, migraine headache, glaucoma, retinitis, urinary incontinence or inducing anesthesia; or enhancing learning and cognition; or treating or ameliorating schizophrenia and myoclonus; comprising administering to an animal in need of such treatment an effective amount of a compound of the Formula I:



Formula I

or a pharmaceutically acceptable salt or a prodrug thereof, wherein:

R<sub>1</sub> is alkyl, haloalkyl, aminoalkyl, C<sub>1-10</sub> alkylaminoalkyl, di(C<sub>1-10</sub>)alkylaminoalkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, cyanoalkyl, alkanoylamidoalkyl, alkanoyloxyalkyl, azidoalkyl, alkenyloxyalkyl, or alkoxyalkyl;


R<sub>6</sub> and R<sub>7</sub> are taken together to form a five or six membered carbocyclic or heterocyclic ring;

R<sub>5</sub> and R<sub>8</sub> are independently selected from the group consisting of hydrogen, halogen, haloalkyl, aryl, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, hydroxyalkyl, nitro, amino, cyano, alkanoylamido, hydroxy, thiol, alkanoyloxy, alkoxy, carboxy, carbonylamido and thioalkoxy;

X is O or S; and

Y is optionally substituted aryl or optionally substituted heteroaryl.

33. A method of treating, preventing or ameliorating neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia or surgery; or treating or ameliorating a neurodegenerative disease selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome; or treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids; or treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, migraine headache, glaucoma, retinitis, urinary incontinence or inducing anesthesia; or enhancing learning and cognition; or treating or ameliorating schizophrenia and myoclonus; comprising administering to an animal in need of such treatment an effective amount of a compound having the Formula II:



Formula II

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R<sub>1</sub> is alkyl, haloalkyl, aminoalkyl, C<sub>1-10</sub> alkylaminoalkyl, di(C<sub>1-10</sub>)alkylaminoalkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, cyanoalkyl, alkanoylamidoalkyl, alkanoyloxyalkyl, azidoalkyl, alkenyloxyalkyl, or alkoxyalkyl;

R<sub>6</sub> and R<sub>7</sub> are taken together to form a five or six membered carbocyclic or heterocyclic ring;

R<sub>5</sub> and R<sub>8</sub> are independently selected from the group consisting of hydrogen, halogen, haloalkyl, aryl, heterocyclic, heteroaryl, alkyl, alkenyl,



alkynyl, aralkyl, aralkenyl, aralkynyl, hydroxyalkyl, nitro, amino, cyano, alkanoylamido, hydroxy, thiol, alkanoyloxy, alkoxy, carboxy, carbonylamido and thioalkoxy;

n is 0 or 1;

5 Y is optionally substituted aryl or optionally substituted heteroaryl;  
and

z is 0 or 1.